Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/Day in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits

NCT00219245 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/Day in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2002
Completion date
January 31, 2005
Enrollment
157 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

traumatic brain injury with persistent cognitive deficits